SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
HROW

Harrow, Inc. (NASDAQ:HROW)

US · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - Specialty & Generic
$30.41-$1.72 (-5.35%)
 
Market cap
$1.14B
Insider Score
Health Score
Analyst consensus
Listed since
Sep 28, 2007
Website
Market Cap$1.14B-22.0%
Revenue (ttm)$303.25M+21.3%
Net Income-$28.49M-471.2%
EPS-$0.77-400.7%
Shares Out37.53M
PE Ration/a
Forward PE20.59
Dividendn/a
Ex-Dividend Daten/a
Volume911,784
Open$31.95
Previous Close$32.13
Day's Range$30.31 - $32.43
52-Week Range$25.76 - $54.85
Beta0.24
AnalystsBuy
Price Target$45.00(+47.98%)
Earnings DateMar 1, 2027

About HROW

Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.

Address
1A Burton Hills Boulevard, Nashville, TN, 37215, US
Market Cap
1.14 billion
Employees
373
Industrial Classification
Drug Manufacturers - Specialty & Generic

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$9.63M
Bought
$468.72K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $73.67 (+142.3%)

1 firm rating HROW in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From HROW’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.35%
5 Days
+2.56%
1 Month
+8.03%
6 Months
-7.85%
1 Year
-22.03%

$HROW stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in HROW holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by HROW's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

HROW Estimated quarterly lobbying spending

Source: U.S. Senate LDA

HROW Revenue by Segment

$182.76MTotal
Branded$83.46M45.67%
VEVYE$39.70M21.72%
IHEEZO$25.30M13.84%
Compounding$15.84M8.66%
TRIESENCE$10.71M5.86%
Other branded products$7.59M4.16%
Other revenues$164.00K0.09%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New HROW patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to HROW from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in HROW

IWMiShares Russell 2000 ETF$26.36M
VTIVanguard Morningstar Total Stock Market ETF$22.29M
FESMFidelity Enhanced Small Cap ETF$12.03M
VXFVanguard Extended Market ETF$10.29M
IWOiShares Russell 2000 Growth ETF$9.73M
XPHState Street SPDR S&P Pharmaceuticals ETF$9.21M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from HROW’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
59.71
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Q3 record revenue and net income growth offset by earnings miss versus estimates; stock rose after hours on results.

Recent Insider Activity

Buys
4
Sells
7
Buy Value
$468.72K
Distinct Buyers
4

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

XPHState Street SPDR S&P Pharmaceuticals ETF1.50%
BCSMBaron ETF Trust - Baron SMID Cap ETF1.17%
FSEGFidelity Enhanced Small Cap Growth ETF0.52%
XHYHBondBloxx USD High Yield Bond Healthcare Sector ETF0.26%
IWCiShares Micro-Cap ETF0.23%
PILLDirexion Daily Pharmaceutical & Medical Bull 3X ETF0.22%
PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF0.21%
IHEiShares U.S. Pharmaceuticals ETF0.19%
FESMFidelity Enhanced Small Cap ETF0.13%
PSCPrincipal U.S. Small-Cap Multi-Factor ETF0.11%
QSMLWisdomTree U.S. SmallCap Quality Growth Fund0.10%
ACSGAmerican Century Small Cap Growth Insights ETF0.09%

Weight is the stock’s share of each fund’s holdings.